X

Trial Profile

A Phase 1/1b Study Evaluating the Safety, Pharmacology, and Clinical Effect of ZH9 Treatment in Patients with Non-Muscle Invasive Bladder Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ZH 9 (Primary)
Indications Bladder cancer
Focus Adverse reactions; First in man
Acronyms PARADIGM-1
Sponsors Prokarium

Most Recent Events

05 Sep 2024 Planned End Date changed from 30 May 2027 to 30 Jul 2027.
05 Sep 2024 Planned primary completion date changed from 3 Feb 2025 to 3 Jun 2025.
07 Feb 2024 According to a Prokarium media release, first patient of this trial has been dosed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com